Company intelligence / Profile preview

Bacoba AG

Wädenswil, Zurich, Switzerlandbacoba.ch ↗

Ownership: Private
Development stage: Other

Overview

Bacoba AG has completed a Phase 1 clinical trial for its lead topical drug candidate BAP5191, assessing safety, tolerability, and pharmacokinetics in healthy adults. The study was randomized, double-blind, and placebo-controlled. No published efficacy results are available as of the latest update.

Therapeutic areas: Infectious Diseases
Modalities: Small moleculesTopical drugs
Industry: Biotech

Beyond the preview

Go deeper on Bacoba AG.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bacoba AG.

Explore the full profile